Table 2.
Some FDA-approved nanocarriers for the treatment of ocular diseases
| Product | Nanocarriers | Drug | Indications | Approval date |
|---|---|---|---|---|
| Visudyne® | Liposome | Verteporfin | Wet age macular degeneration | 2000 |
| Durezol® | Nanoemulsion | Difluprednate | Postoperative ocular inflammation | 2002 |
| Restasis® | Nanoemulsion | Cyclosporine A | Dry eye disease | 2002 |
| Retisert® | Implant | Fluclorolone | Uveitis and macular edema | 2005 |
| Triesence® | Nanoparticles | Triamcinolone acetonide | Dry eye disease | 2007 |
| AzaSite® | Micelles | Azithromycin | DED; keratitis; eye inflammation | 2007 |
| Durezol® | Nanoemulsion | Difluprednate | Eye infection and pain | 2008 |
| Cationorm® | Nanoemulsion | Medical device | Dry eye disease | 2008 |
| Trivaris™ | Nanoparticles | Triamcinolone acetonide | Uveitis | 2008 |
| Besivance® | Nanosuspension | Besifloxacin | Ocular bacterial infection | 2009 |
| Tobradex ST® | Nanosuspension | Tobramycin Dexamethasone | Ocular inflammation and bacterial infection | 2009 |
| Ikervis® | Nanoemulsion | Cyclosporine A | Keratitis | 2015 |
| BromSite® | Solution | Bromfenac | Postoperative inflammation and pain | 2016 |
| Cequa® | Micelle | Cyclosporine A | Dry eye disease | 2018 |
| Inveltys® | Nanosuspension | Loteprednol etabonate | Postoperative ocular inflammation and pain | 2018 |
| Xelpros® | Nanoemulsion | Latanopros | Open-angle glaucoma or high intraocular pressure | 2018 |
| Eysuvis® | Nanosuspension | Loteprednol etabonate | Dry eye disesae | 2020 |
| Verkazia® | Nanoemulsion | Cyclosporine | Vernal keratoconjunctivitis | 2021 |
| Cyclokat® | Nanoemulsion | Cyclosporine A | Dry eye disease | NA |
| Lacrisek® | Liposomal spray | Vitamin A, E | Dry eye disease | NA |
| Artelac Rebalance® | Liposomal eye drops | Vitamin B12 | Dry eye disease | NA |